“Whilst the process of finalising the terms of the Exclusive Licence Agreement has taken the parties past the 28 February expiry date in the binding letter of intent, both organisations have already committed substantial resources towards a successful roll-out of PromarkerD across the USA and are still working actively together to achieve this.” said Proteomics International Managing Director, Dr Richard Lipscombe
Article: Proteomics nears agreement to sell kidney disease test in USA
